US Blood Cancer Market Space Analysed in New Topical Kuick Research Report Now Available at MarketPublishers.com
20 Aug 2015 • by Natalie Aster
LONDON – Pharmaceutical companies have discovered the opportunities to generate considerable revenues from the blood cancer sector in the United States. Increasing blood cancer incidence cases, high levels of unmet medical needs and the demand for better therapeutics are a number of key factors lying behind growth of the domestic blood cancer market. Increased investments have been made by pharmacos to come forward with better therapeutics for producing impressive revenues. Thus, manifold therapeutic agents have been introduced in the country’s market for the successful therapy of blood cancer. A number of novel therapeutics are currently at various clinical trial stages which would be introduced in the years to come.
In the coming years, innovative blood cancer therapeutics will likely generate massive revenues for the pharmacos. Nevertheless, some hurdles have to be taken such as the heterogeneous nature of blood cancer. In that vein, only single therapeutic for various blood cancer types have been introduced in the local market up to this date. This strategy is expected to be followed by other pharmacos owing to which competition in multitudinous blood cancer segments will likely intensify. Market introduction of such therapeutics is anticipated to be broadly accepted resulting in the creation of significant revenues. More blood cancer therapeutics is forecast to come into the US market owing to which its size is set to grow.
New report “US Blood Cancer Drug Market & Pipeline Analysis 2015” developed by Kuick Research gives a bird’s eye view of the US blood cancer market. The study presents details about blood cancer incidence and prevalence rates, discusses the mechanism of blood cancer therapeutics. It further provides an overview of the actual scenario of the blood cancer drug market and sheds light on the overall clinical pipeline. The study analyses the blood cancer drug market dynamics, assesses the positive factors impacting the sector and canvasses the challenges associated with the commercialisation of new drug products. It offers insights into the clinical pipeline of the 435 drugs targeting leukemia, lymphoma and myeloma; details the 128 drug products in Phase I clinical studies. The report provides an analysis of the 48 marketed leukemia, lymphoma and myeloma drugs along with a patent analysis. It also canvasses the competitive landscape and provides granular profiles of the leading 32 companies.
US Blood Cancer Drug Market & Pipeline Analysis 2015
Published: July, 2015
Price: US$ 3,000.00
More studies by the publisher can be found at Kuick Research page.